- Home
- ARTW vs PMI Comparison
ARTW vs PMI Comparison
Compare ARTW & PMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ARTW | PMI |
|---|---|---|
| Founded | 1956 | 1981 |
| Country | United States | United States |
| Employees | N/A | 75 |
| Industry | Industrial Machinery/Components | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4M | 14.1M |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | ARTW | PMI |
|---|---|---|
| Price | $2.70 | $0.13 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 11.8K | ★ 13.1M |
| Earning Date | 04-13-2026 | 06-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 233.33 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $22,975,408.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $66.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.69 | $0.11 |
| 52 Week High | $4.69 | $13.68 |
Technical Indicators
Market Signals| Indicator | ARTW | PMI |
|---|---|---|
| Relative Strength Index (RSI) | 53.99 | 17.61 |
| Support Level | $2.07 | N/A |
| Resistance Level | $2.96 | $0.27 |
| Average True Range (ATR) | 0.10 | 0.03 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 48.21 | 16.24 |
Price Performance
Historical ComparisonAbout ARTW Art's-Way Manufacturing Co. Inc.
Art's-Way Manufacturing Co Inc is a manufacturer of agricultural equipment. It has two reportable segments: Agricultural Products and Modular Buildings. The Agricultural Products segment fabricates and sells farming products as well as related equipment and replacement parts for these products in the United States and world wide. Its Modular Buildings segment manufactures and installs modular buildings for animal containment and various laboratory uses. It derives revenues from the Agricultural Products segment.
About PMI Picard Medical Inc.
Picard Medical Inc operates through its wholly owned subsidiary, a medical technology company focused on developing, manufacturing, and commercializing the SynCardia TAH, an implantable total artificial heart system. The company is engaged in designing, manufacturing, producing, supplying, marketing, and selling medical device products, including the SynCardia TAH, which is designed to assume the full function of a failed human heart in patients suffering from advanced heart failure. The SynCardia TAH replaces both the left and right ventricles as well as all four heart valves.